Therapeutics across CNS, immunology & inflammation and beyond: clinical readouts, approvals, licensing and BD deals, and leadership moves at clinical- and commercial-stage pharma and biotech.
Every story from Tx Weekly, newest first.
$1.275bn upfront for Phase 1 HCXT-2001, days after its own oral IBD drug emvistegrast hit in Phase 2. An all-oral IBD combination is the plan.
Read the full story →$20 per ADS, about $1.3bn in equity value, for divesiran in polycythemia vera. Merck KGaA's entry into haematology.
Read the full story →Sanofi and Teva's anti-TL1A antibody kept up to 58% of UC responders in remission. Four Phase 3 trials are already running.
Read the full story →Brezosiran cut mutant huntingtin by 60–64% in its top dose group. A placebo-controlled pivotal study is planned for 2027.
Read the full story →US share is down to 26% from 56% in 2024, per Locust Walk. A proposed US Treasury rule on China biotech investment exempts licensing.
Read the full story →Harry Aaronson specialises in Therapeutics hiring at QP Group. Talk to Harry about the market, salaries or a search.
The full archive of Tx Weekly.
A three-minute weekly read: funding, launches, leadership moves and what they mean for hiring. Written by Harry Aaronson. No spam, one-click unsubscribe.
